| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
7,596 |
7,073 |
$950K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
1,941 |
1,654 |
$726K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
2,374 |
2,166 |
$577K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
1,583 |
1,488 |
$245K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
1,871 |
1,788 |
$143K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
591 |
537 |
$103K |
| G0378 |
Hospital observation service, per hour |
47 |
39 |
$26K |
| 99291 |
Critical care, evaluation and management of the critically ill patient, first 30-74 minutes |
35 |
31 |
$18K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
644 |
196 |
$12K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
621 |
228 |
$11K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
1,338 |
1,228 |
$11K |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
60 |
57 |
$7K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
1,495 |
1,302 |
$3K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
444 |
375 |
$2K |
| 96376 |
|
126 |
101 |
$2K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
121 |
113 |
$2K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
27 |
27 |
$1K |
| 84443 |
Thyroid stimulating hormone (TSH) |
121 |
99 |
$1K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
9,340 |
8,751 |
$908.54 |
| 96361 |
Intravenous infusion, hydration; each additional hour |
1,039 |
915 |
$738.29 |
| 80053 |
Comprehensive metabolic panel |
3,379 |
2,819 |
$703.00 |
| 71045 |
Radiologic examination, chest; single view |
1,558 |
1,340 |
$541.68 |
| 70450 |
Computed tomography, head or brain; without contrast material |
389 |
352 |
$438.77 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,002 |
875 |
$431.44 |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
106 |
97 |
$384.62 |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
1,873 |
1,662 |
$315.52 |
| 71046 |
Radiologic examination, chest; 2 views |
132 |
114 |
$202.93 |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
1,119 |
1,023 |
$170.20 |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
3,907 |
3,094 |
$168.40 |
| 84484 |
|
1,500 |
1,139 |
$151.90 |
| 36415 |
Collection of venous blood by venipuncture |
320 |
235 |
$151.50 |
| 96375 |
Therapeutic injection; each additional sequential IV push |
1,554 |
1,357 |
$133.45 |
| 83880 |
|
159 |
136 |
$128.07 |
| 83735 |
|
1,994 |
1,584 |
$68.25 |
| 81001 |
|
1,469 |
1,311 |
$49.10 |
| 85610 |
|
1,203 |
1,035 |
$45.39 |
| 85730 |
|
898 |
776 |
$45.01 |
| 83690 |
|
1,345 |
1,177 |
$43.76 |
| 87186 |
|
77 |
68 |
$27.97 |
| 80048 |
Basic metabolic panel (calcium, ionized) |
521 |
377 |
$27.69 |
| 81025 |
|
791 |
729 |
$23.86 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
345 |
332 |
$23.53 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
572 |
508 |
$21.80 |
| 85379 |
|
198 |
179 |
$19.26 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
417 |
373 |
$17.70 |
| 87081 |
|
274 |
262 |
$16.58 |
| 80306 |
|
243 |
227 |
$15.96 |
| 84702 |
|
14 |
13 |
$15.12 |
| 83605 |
|
607 |
506 |
$10.34 |
| 81003 |
|
690 |
613 |
$10.34 |
| 82962 |
|
316 |
161 |
$5.36 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
136 |
120 |
$5.25 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
327 |
300 |
$4.88 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
1,243 |
1,112 |
$4.55 |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
461 |
397 |
$0.32 |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
44 |
38 |
$0.23 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
95 |
88 |
$0.00 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
134 |
116 |
$0.00 |
| A9270 |
Non-covered item or service |
555 |
275 |
$0.00 |
| J2704 |
Injection, propofol, 10 mg |
280 |
246 |
$0.00 |
| J3490 |
Unclassified drugs |
268 |
200 |
$0.00 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
257 |
216 |
$0.00 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
190 |
161 |
$0.00 |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
35 |
25 |
$0.00 |
| 97016 |
|
127 |
38 |
$0.00 |
| 86901 |
|
14 |
12 |
$0.00 |
| J2060 |
Injection, lorazepam, 2 mg |
14 |
12 |
$0.00 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
14 |
12 |
$0.00 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
15 |
12 |
$0.00 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
319 |
279 |
$0.00 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
281 |
260 |
$0.00 |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
63 |
62 |
$0.00 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
243 |
206 |
$0.00 |
| 84100 |
|
14 |
12 |
$0.00 |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
12 |
12 |
$0.00 |
| 86900 |
|
14 |
12 |
$0.00 |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
13 |
13 |
$0.00 |